beta-alanine has been researched along with Breast Cancer in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients." | 6.78 | Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. ( Barupal, DK; Brockmöller, SF; Budczies, J; Denkert, C; Dietel, M; Fiehn, O; Griffin, JL; Kleine-Tebbe, A; Müller, BM; Orešič, M; Richter-Ehrenstein, C, 2013) |
| "Capecitabine (Xeloda) is a novel, oral fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue via a three-step enzymatic cascade." | 6.71 | Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. ( Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C, 2003) |
| "Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients." | 2.78 | Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. ( Barupal, DK; Brockmöller, SF; Budczies, J; Denkert, C; Dietel, M; Fiehn, O; Griffin, JL; Kleine-Tebbe, A; Müller, BM; Orešič, M; Richter-Ehrenstein, C, 2013) |
| "Capecitabine (Xeloda) is a novel, oral fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue via a three-step enzymatic cascade." | 2.71 | Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. ( Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C, 2003) |
| "Studies were undertaken with Ehrlich ascites tumor and bone marrow cells isolated from CF-1 mice." | 1.27 | Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. ( Diasio, RB; Schuetz, JD; Sommadossi, JP; Wallace, HJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budczies, J | 2 |
| Brockmöller, SF | 1 |
| Müller, BM | 1 |
| Barupal, DK | 1 |
| Richter-Ehrenstein, C | 1 |
| Kleine-Tebbe, A | 1 |
| Griffin, JL | 1 |
| Orešič, M | 1 |
| Dietel, M | 1 |
| Denkert, C | 1 |
| Fiehn, O | 1 |
| Vaughan, RA | 1 |
| Gannon, NP | 1 |
| Garcia-Smith, R | 1 |
| Licon-Munoz, Y | 1 |
| Barberena, MA | 1 |
| Bisoffi, M | 1 |
| Trujillo, KA | 1 |
| Retzloff, LB | 1 |
| Heinzke, L | 1 |
| Figureoa, SD | 1 |
| Sublett, SV | 1 |
| Ma, L | 1 |
| Sieckman, GL | 1 |
| Rold, TL | 1 |
| Santos, I | 1 |
| Hoffman, TJ | 1 |
| Smith, CJ | 1 |
| Reigner, B | 1 |
| Watanabe, T | 1 |
| Schüller, J | 1 |
| Lucraft, H | 1 |
| Sasaki, Y | 1 |
| Bridgewater, J | 1 |
| Saeki, T | 1 |
| McAleer, J | 1 |
| Kuranami, M | 1 |
| Poole, C | 1 |
| Kimura, M | 1 |
| Monkhouse, J | 1 |
| Yorulmaz, C | 1 |
| Weidekamm, E | 1 |
| Grange, S | 1 |
| Shennan, DB | 1 |
| Thomson, J | 1 |
| Wang, J | 1 |
| Masuko, T | 1 |
| Ueno, H | 1 |
| Hashimoto, Y | 1 |
| Diasio, RB | 1 |
| Schuetz, JD | 1 |
| Wallace, HJ | 1 |
| Sommadossi, JP | 1 |
1 review available for beta-alanine and Breast Cancer
| Article | Year |
|---|---|
[Metabolome analysis of solid tumors].
Topics: 4-Aminobutyrate Transaminase; beta-Alanine; Biomarkers, Tumor; Breast; Breast Neoplasms; Colonic Neo | 2016 |
2 trials available for beta-alanine and Breast Cancer
| Article | Year |
|---|---|
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.
Topics: beta-Alanine; Breast Neoplasms; Female; Genome-Wide Association Study; Glutamine; Humans; Metabolome | 2013 |
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biotransformation; Bre | 2003 |
5 other studies available for beta-alanine and Breast Cancer
| Article | Year |
|---|---|
β-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro.
Topics: beta-Alanine; Blotting, Western; Breast Neoplasms; Flow Cytometry; Glycolysis; Humans; Hydrogen-Ion | 2014 |
Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma.
Topics: Animals; beta-Alanine; Bombesin; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; | 2010 |
Estrogen regulation and ion dependence of taurine uptake by MCF-7 human breast cancer cells.
Topics: beta-Alanine; Breast Neoplasms; Chlorides; Estradiol; Estrogens; Extracellular Space; Female; Humans | 2007 |
Alterations of specific and nonspecific binding of monoclonal antibody by introduction of acidic and hydrophobic groups.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; beta-Alanine; Binding Sites, Antibody; Breast | 1994 |
Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
Topics: Animals; Antineoplastic Agents; beta-Alanine; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell Line; | 1985 |